ECOR1 CAPITAL
EcoR1 Capital is a biotech-focused investment advisory firm.
ECOR1 CAPITAL
Social Links:
Industry:
Biotechnology Financial Services
Founded:
2012-01-01
Status:
Active
Contact:
415-754-3517
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics
Similar Organizations
BioMedPartners
BioMedPartners is one of the leading European venture capital firms.
gumi Cryptos Capital (gCC)
gumi Cryptos Capital is a blockchain and cryptographic asset venture fund
Logos Capital
Logos Capital is a fundamental biotechnology-focused investment fund.
LYFE Capital
LYFE Capital is a life science investment firm.
Polaris Partners
Polaris Partners is an investment firm that invests in healthcare and biotechnology companies.
RA Capital Management
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Refactor Capital
Refactor Capital is a seed stage VC firm investing in bio, climate, and health.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-09-07 | SpringWorks Therapeutics | EcoR1 Capital investment in Post-IPO Equity - SpringWorks Therapeutics | 225 M USD |
| 2022-08-25 | Aktis Oncology | EcoR1 Capital investment in Series A - Aktis Oncology | 84 M USD |
| 2022-08-19 | Kymera Therapeutics | EcoR1 Capital investment in Post-IPO Equity - Kymera Therapeutics | 150 M USD |
| 2022-07-27 | AlloVir | EcoR1 Capital investment in Post-IPO Equity - AlloVir | 126.6 M USD |
| 2022-07-13 | Gossamer Bio | EcoR1 Capital investment in Post-IPO Equity - Gossamer Bio | 120 M USD |
| 2022-04-27 | Tempest Therapeutics | EcoR1 Capital investment in Post-IPO Equity - Tempest Therapeutics | 15 M USD |
| 2022-03-16 | 2seventy bio | EcoR1 Capital investment in Post-IPO Equity - 2seventy bio | 170 M USD |
| 2022-02-03 | Dewpoint Therapeutics | EcoR1 Capital investment in Series C - Dewpoint Therapeutics | 150 M USD |
| 2022-01-06 | Eikon Therapeutics | EcoR1 Capital investment in Series B - Eikon Therapeutics | 518 M USD |
| 2021-12-27 | Pardes Biosciences | EcoR1 Capital investment in Post-IPO Equity - Pardes Biosciences | 75 M USD |
More informations about "EcoR1 Capital"
EcoR1 Capital - Crunchbase Investor Profile
EcoR1 Capital is an investment advisory firm focused on the biotech industry. They aim to identify and evaluate innovative therapeutic solutions that can …See details»
About | EcoR1 Capital
Like the EcoR1 restriction enzyme which transformed the biomedical field, we help move …See details»
EcoR1 Capital - Investments, Portfolio & Company Exits
EcoR1 Capital 's most notable exits include Avidity Biosciences, Immunome, and Kronos Bio. …See details»
Item 1. Cover Page Brochure of EcoR1 Capital, LLC San Francisco, …
EcoR1 Capital, LLC (“EcoR1”) is a limited liability company that has been in business since …See details»
ECOR1 CAPITAL, LLC Top 13F Holdings - WhaleWisdom.com
Ecor1 Capital is based out of San Francisco. Ecor1 Capital is a hedge fund with 5 clients and …See details»
Portfolio | EcoR1 Capital
There can be no assurance that the investments referenced were, are, or will be, profitable. This is for information purposes only and should not be construed as an investment recommendation or offer to invest in any fund managed by …See details»
Ecor1 Capital 13F annual report (2024) - wallmine
64 rows Ecor1 Capital closed its position in Alector on 14th August 2024. It sold the …See details»
List of top EcoR1 Capital Portfolio Companies - Crunchbase
Nov 19, 2013 EcoR1 Capital is a biotech-focused investment advisory firm. This list of …See details»
What’s Behind EcoR1’s Healthy Returns - Institutional …
Jan 21, 2022 EcoR1 Capital was launched in March 2013 by Oleg Nodelman, who was once named an II Hedge Fund Rising Star. The firm, which focuses on therapeutic companies within the biotechnology sector ...See details»
EcoR1 Capital, LLC Acquires Significant Stake in …
Jul 28, 2023 The transaction took place on July 27, 2023, with EcoR1 Capital, LLC (Trades, Portfolio) purchasing 19,331,910 shares of Mersana Therapeutics Inc. This acquisition had a 2.38% impact on the firm's ...See details»
The 2015 Hedge Fund Rising Stars: Oleg Nodelman - Institutional …
Jun 15, 2015 The 2015 Hedge Fund Rising Stars: Oleg Nodelman Nodelman’s EcoR1 Capital …See details»
Galapagos’ stock up as fund shows intent to shape its evolution
Aug 26, 2024 Having built a 9.9% stake in Galapagos, EcoR1 Capital is now planning to talk …See details»
Institutional Top Ideas: EcoR1 Capital - Seeking Alpha
Jun 12, 2018 Summary. Returns for EcoR1 Capital are quite impressive. It is significantly …See details»
EcoR1 Capital - Funding, Financials, Valuation & Investors
EcoR1 Capital has raised a total of $479.2M across 4 funds, their latest being EcoR1 Venture …See details»
EcoR1 Capital's second SPAC Panacea Acquisition II files for a
Mar 9, 2021 The article EcoR1 Capital's second SPAC Panacea Acquisition II files for a $150 …See details»
EcoR1 Goes Bottom-Fishing - Institutional Investor
Jul 31, 2023 In recent weeks, EcoR1 Capital has sharply boosted its stake in at least four of …See details»
Oleg Nodelman - Founder & Managing Director @ EcoR1 Capital ...
Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital LLC, a biotech …See details»
Team | EcoR1 Capital
EcoR1 Capital, LLC 357 Tehama Street, Floor 3 San Francisco, CA 94103See details»
Paris dreams of becoming the capital of positive AI with the ...
1 day ago France will host 100 heads of state and some 600 business and NGO leaders from …See details»
EcoR1 Capital - Contacts, Employees, Board Members
EcoR1 Capital has 6 current employee profiles, including Investor Scott Platshon. Contacts. …See details»